Express Scripts' Steve Miller has launched a crusade on high-priced specialty drugs. He calls the $84,000 price tag on Gilead Science's new hepatitis C drug Sovaldi a case of unfair pricing at its worst. "We have never had a single product that has been such a threat to the payer community," argued the chief medical officer of the nation's largest pharmacy benefit company. "If we treat everyone it would be $300 billion." Bertha Coombs interviews Dr. Miller at Express Scripts' pharmacy headquarters in Saint Louis.